` LENZ (Graphite Bio Inc) vs S&P 500 Comparison - Alpha Spread

LENZ
vs
S&P 500

Over the past 12 months, LENZ has underperformed S&P 500, delivering a return of -42% compared to the S&P 500's +14% growth.

Stocks Performance
LENZ vs S&P 500

Loading
LENZ
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
LENZ vs S&P 500

Loading
LENZ
S&P 500
Difference
www.alphaspread.com

Performance By Year
LENZ vs S&P 500

Loading
LENZ
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Graphite Bio Inc vs Peers

S&P 500
LENZ
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Graphite Bio Inc
Glance View

Market Cap
513m USD
Industry
Biotechnology

Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).

LENZ Intrinsic Value
32.88 USD
Undervaluation 45%
Intrinsic Value
Price
Back to Top